2026 Q2 - tulosraportti
43 päivää sitten
‧30 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 350 | - | - | ||
| 135 | - | - | ||
| 1 715 | - | - | ||
| 337 | - | - | ||
| 1 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
Liiketoimintakatsaus 16.1. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenI am down -97 percent on this stock 🥶
I identified an entry point at the red dashed line five trading days ago, and bought 40000 shares this morning at 2.03. Have captured pretty much the entire day's upward move, corresponding to almost +45%, just saying it 😂😂
·4 t sittenHere we go, we should probably reach 10 kr if the flexibility process handling is fully met and they get a solid hit to eventually gain traction in the US via FDA approval.
·5 t sitten · MuokattuDoes not work - melflufen's limitations in solid tumors The 2015 clinical study clearly demonstrated melflufen's limitations in solid tumors, where only 1 of 27 patients achieved a partial response and the effect against, for example, non-small cell lung cancer (NSCLC) was described as very modest. The fact that melflufen as monotherapy had such difficulty shrinking established solid tumor masses in the body strongly suggests that it will encounter similar, if not even tougher, biological resistance in such an aggressive tumor as glioblastoma. Lung cancer and ovarian cancer are easily reached by systemic chemotherapies via the blood, but melflufen still gave a poor effect there. When researchers nevertheless choose to test the drug in the ongoing INSULA study, it is due to a specific anatomical difference: the solid tumors in the 2015 study were easily reached by the drug via the blood but still did not respond, whereas glioblastoma normally completely blocks medicines via the blood-brain barrier. Recent interim data show that melflufen actually manages to penetrate this barrier and enter brain tissue. But penetration is not the same as efficacy. Glioblastoma are notorious for their cellular heterogeneity and their extremely efficient systems for repairing DNA damage. Even if melflufen reaches the target and is activated by the enzymes (aminopeptidases) present in the tumor, there is a very high risk that the glioblastoma's inherent resistance mechanisms neutralize the effect - in exactly the same way as happened in the majority of the solid tumors in the 2015 study. That the drug has found its way to the tumor is an advance, but until the study can show actual tumor shrinkage or prolonged survival in patients, there is currently no clinical evidence that efficacy will be better. https://link.springer.com/article/10.1007/s10637-015-0299-2 My opinion and no advice.Response Evaluation Criteria In Solid Tumors (RECIST) evaluation after 3 cycles of therapy (27 patients) showed partial response in one (ovarian cancer), and stable disease in 18 patients. One NSCLC patient received nine cycles of melflufen and progressed after 7 months of therapy. Conclusions In conclusion, melflufen can safely be given to cancer patients, and the toxicity profile was as expected for alkylating agents; RPTD is 50 mg Q3W. Reversible and manageable bone marrow suppression was identified as a DLT. Clinical activity is suggested in ovarian cancer, but modest activity in treatment of refractory NSCLC. My opinion and no advice.
·7 t sittenall you lucky riders please do not sell out for cheap mammon hold on tight it will be worth much more :-) so please do not sell quickly again short has risen nicely the last 14 days think they want out so hold on tight- ·7 t sittenMy opinion and not advice 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
43 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenI am down -97 percent on this stock 🥶I identified an entry point at the red dashed line five trading days ago, and bought 40000 shares this morning at 2.03. Have captured pretty much the entire day's upward move, corresponding to almost +45%, just saying it 😂😂
- ·4 t sittenHere we go, we should probably reach 10 kr if the flexibility process handling is fully met and they get a solid hit to eventually gain traction in the US via FDA approval.
- ·5 t sitten · MuokattuDoes not work - melflufen's limitations in solid tumors The 2015 clinical study clearly demonstrated melflufen's limitations in solid tumors, where only 1 of 27 patients achieved a partial response and the effect against, for example, non-small cell lung cancer (NSCLC) was described as very modest. The fact that melflufen as monotherapy had such difficulty shrinking established solid tumor masses in the body strongly suggests that it will encounter similar, if not even tougher, biological resistance in such an aggressive tumor as glioblastoma. Lung cancer and ovarian cancer are easily reached by systemic chemotherapies via the blood, but melflufen still gave a poor effect there. When researchers nevertheless choose to test the drug in the ongoing INSULA study, it is due to a specific anatomical difference: the solid tumors in the 2015 study were easily reached by the drug via the blood but still did not respond, whereas glioblastoma normally completely blocks medicines via the blood-brain barrier. Recent interim data show that melflufen actually manages to penetrate this barrier and enter brain tissue. But penetration is not the same as efficacy. Glioblastoma are notorious for their cellular heterogeneity and their extremely efficient systems for repairing DNA damage. Even if melflufen reaches the target and is activated by the enzymes (aminopeptidases) present in the tumor, there is a very high risk that the glioblastoma's inherent resistance mechanisms neutralize the effect - in exactly the same way as happened in the majority of the solid tumors in the 2015 study. That the drug has found its way to the tumor is an advance, but until the study can show actual tumor shrinkage or prolonged survival in patients, there is currently no clinical evidence that efficacy will be better. https://link.springer.com/article/10.1007/s10637-015-0299-2 My opinion and no advice.Response Evaluation Criteria In Solid Tumors (RECIST) evaluation after 3 cycles of therapy (27 patients) showed partial response in one (ovarian cancer), and stable disease in 18 patients. One NSCLC patient received nine cycles of melflufen and progressed after 7 months of therapy. Conclusions In conclusion, melflufen can safely be given to cancer patients, and the toxicity profile was as expected for alkylating agents; RPTD is 50 mg Q3W. Reversible and manageable bone marrow suppression was identified as a DLT. Clinical activity is suggested in ovarian cancer, but modest activity in treatment of refractory NSCLC. My opinion and no advice.
- ·7 t sittenall you lucky riders please do not sell out for cheap mammon hold on tight it will be worth much more :-) so please do not sell quickly again short has risen nicely the last 14 days think they want out so hold on tight
- ·7 t sittenMy opinion and not advice 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 350 | - | - | ||
| 135 | - | - | ||
| 1 715 | - | - | ||
| 337 | - | - | ||
| 1 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
Liiketoimintakatsaus 16.1. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
43 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
Liiketoimintakatsaus 16.1. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenI am down -97 percent on this stock 🥶I identified an entry point at the red dashed line five trading days ago, and bought 40000 shares this morning at 2.03. Have captured pretty much the entire day's upward move, corresponding to almost +45%, just saying it 😂😂
- ·4 t sittenHere we go, we should probably reach 10 kr if the flexibility process handling is fully met and they get a solid hit to eventually gain traction in the US via FDA approval.
- ·5 t sitten · MuokattuDoes not work - melflufen's limitations in solid tumors The 2015 clinical study clearly demonstrated melflufen's limitations in solid tumors, where only 1 of 27 patients achieved a partial response and the effect against, for example, non-small cell lung cancer (NSCLC) was described as very modest. The fact that melflufen as monotherapy had such difficulty shrinking established solid tumor masses in the body strongly suggests that it will encounter similar, if not even tougher, biological resistance in such an aggressive tumor as glioblastoma. Lung cancer and ovarian cancer are easily reached by systemic chemotherapies via the blood, but melflufen still gave a poor effect there. When researchers nevertheless choose to test the drug in the ongoing INSULA study, it is due to a specific anatomical difference: the solid tumors in the 2015 study were easily reached by the drug via the blood but still did not respond, whereas glioblastoma normally completely blocks medicines via the blood-brain barrier. Recent interim data show that melflufen actually manages to penetrate this barrier and enter brain tissue. But penetration is not the same as efficacy. Glioblastoma are notorious for their cellular heterogeneity and their extremely efficient systems for repairing DNA damage. Even if melflufen reaches the target and is activated by the enzymes (aminopeptidases) present in the tumor, there is a very high risk that the glioblastoma's inherent resistance mechanisms neutralize the effect - in exactly the same way as happened in the majority of the solid tumors in the 2015 study. That the drug has found its way to the tumor is an advance, but until the study can show actual tumor shrinkage or prolonged survival in patients, there is currently no clinical evidence that efficacy will be better. https://link.springer.com/article/10.1007/s10637-015-0299-2 My opinion and no advice.Response Evaluation Criteria In Solid Tumors (RECIST) evaluation after 3 cycles of therapy (27 patients) showed partial response in one (ovarian cancer), and stable disease in 18 patients. One NSCLC patient received nine cycles of melflufen and progressed after 7 months of therapy. Conclusions In conclusion, melflufen can safely be given to cancer patients, and the toxicity profile was as expected for alkylating agents; RPTD is 50 mg Q3W. Reversible and manageable bone marrow suppression was identified as a DLT. Clinical activity is suggested in ovarian cancer, but modest activity in treatment of refractory NSCLC. My opinion and no advice.
- ·7 t sittenall you lucky riders please do not sell out for cheap mammon hold on tight it will be worth much more :-) so please do not sell quickly again short has risen nicely the last 14 days think they want out so hold on tight
- ·7 t sittenMy opinion and not advice 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 350 | - | - | ||
| 135 | - | - | ||
| 1 715 | - | - | ||
| 337 | - | - | ||
| 1 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt